The Truth About Heart Disease: Why Insulin Resistance Matters More Than LDL

A Comprehensive, Evidence-Based Guide to Metabolic Health and Cardiovascular Risk

---

Preface: The Paradigm Shift We’ve Been Waiting For

I am still getting people being warned off from ketogenic diets—often prescribed for mental illness, type 2 diabetes, or metabolic dysfunction—because of LDL concerns. I am not sure what doctors need, but they have been told to catch up by their own professional organizations for a long time.

Cardiology organizations have advised against using LDL cholesterol as the only marker for guiding statin prescriptions since 2013, when the American College of Cardiology (ACC) and American Heart Association (AHA) issued updated guidelines. Those guidelines moved away from the “treat‑to‑target” LDL‑only approach and instead recommended fixed doses of statin therapy based on overall cardiovascular risk.

So it has been over a decade since the field formally shifted away from relying solely on LDL as the determinant for statin use.

And yet, doctors are still handing out statins based on total cholesterol alone.

This guide represents the synthesis of hundreds of research papers, decades of clinical experience from leading physicians, and the metabolic success stories of hundreds of thousands of individuals who have reclaimed their health by questioning conventional wisdom.

---

Part I: The Landmark Study Everyone Should Know

The Women’s Health Study: What Actually Predicts Premature Heart Disease

A 2022 study published in BMC Medicine examined risk profiles for incident cardiovascular disease (CVD) by age at onset in a Chinese population of nearly 100,000 participants (97,841 to be exact). The findings are remarkably clear:

“These findings showed that diabetes and insulin resistance, in addition to hypertension, metabolism syndrome, overweight or obese, dyslipidemia, and smoking, appeared to be the strongest risk factors for premature onset of CVD, and most risk factors had attenuated relative rates at older ages.” (BMC Medicine, 2022)

Link to full study

The Key Finding Visualized

In the paper, three critical relationships emerge:

This is not a minor finding. This is a massive, well-powered prospective study demonstrating that metabolic health trumps LDL cholesterol every single time.

The triglyceride-glucose index (TyG)—calculated as ln(fasting triglycerides [mg/dL] × fasting glucose [mg/dL]/2)—outperformed every lipid marker in predicting cardiovascular events.

Why This Matters

If you want to prevent heart disease, you should be far more concerned about:

• Diabetes (4x risk)

• Insulin resistance (TyG index)

• Hypertension

• Metabolic syndrome

• Smoking

• Obesity

Than you should be about your LDL number.

---

Part II: The Most Important Lipid Panel Marker

Why LDL Fails as a Predictor

In a large cohort of people hospitalized for cardiovascular disease—a total of 136,905 hospitalizations—”almost half have admission LDL levels <100 mg/dL” (Sachdeva et al., 2009). Their LDL was normal, yet they had heart disease.

The following relationship, derived from multiple studies, shows that LDL only matters in the context of low HDL. If you have high HDL, then high LDL is barely a risk factor. If you have low HDL, however, watch out.

The Triglyceride/HDL Ratio

The triglyceride/HDL ratio appears to be the most powerful lipid marker for heart disease risk. The lower, the better.

Consider this finding from a prospective study of 2,906 men aged 53–74 years followed for 7 years: Those in the top quartile of the triglycerides/HDL ratio had 16 times the risk of heart attack as those in the lowest quartile (Jeppesen et al., 1997).

This relationship has been confirmed in numerous studies:

A high ratio of triglycerides to HDL predicts extensive coronary artery disease. Of all the lipid markers, “only TG/HDL-c and HDL-c were useful for detecting extensive coronary disease, with the former more strongly associated with disease” (Dobiášová & Frohlich, 2001).

Let me repeat: No significant relationship was found between total cholesterol or LDL and coronary disease extent.

Men with a low triglycerides/HDL ratio had a low risk of ischemic heart disease, even when they had other risk factors:

“Men with conventional risk factors for IHD have a low risk of IHD if they have low TG–high HDL-C levels” (Jeppesen et al., 2001).

This means that even if you smoke, have hypertension, or are obese, a low triglycerides/HDL ratio appears to be protective—a finding that deserves far more attention than it receives.

What Are Good Numbers?

• TG/HDL < 2.0: Ideal (Sinatra, 2008)

• TG/HDL < 1.0: Optimal

• TG/HDL > 4.0: Critical intervention needed

(Note: You must use American units of mg/dL, not mmol/L, for these ratios. To convert mmol/L triglycerides to mg/dL, multiply by 88.5; HDL mmol/L to mg/dL, multiply by 38.6.)

My last check was 0.5. It is difficult to get lower than that.

What Does This Ratio Mean Physiologically?

The triglycerides/HDL ratio is a direct proxy for insulin resistance (McLaughlin et al., 2003). It correlates strongly with:

• Fasting insulin levels

• Direct measures of insulin sensitivity (hyperinsulinemic-euglycemic clamp)

• Small, dense LDL particle concentration

• Visceral adiposity

When triglycerides rise and HDL falls, it reflects:

1. Increased VLDL production from the liver (driven by hepatic insulin resistance)

2. Accelerated HDL clearance (HDL becomes triglyceride-enriched and unstable)

3. Cholesterol ester transfer protein (CETP)-mediated remodeling of LDL toward small, dense particles

Is there a simple way to identify insulin-resistant individuals at high risk for cardiovascular disease? Yes, a triglyceride/HDL ratio of >3.5 identifies them with high sensitivity and specificity (McLaughlin et al., 2003).

---

Part III: David Diamond on LDL—A Lipidologist’s Perspective

In the past several years, editors have been sending manuscripts on diet and heart disease to Dr. David Diamond, a lipidologist and professor, as part of the peer-review process. The following text is from a review he wrote evaluating a manuscript that promoted the DASH diet while criticizing low-carbohydrate diets:

“The idea that the first stage of atherosclerosis is the accumulation of LDL-C is not supported by a broader assessment of the literature. If high LDL-C simply gains access to the artery wall, thereby choking off the artery and causing premature CVD death, then all people with high LDL-C should die prematurely of CVD. “

“Whether one reads the older [1] or recent [2] literature, one finds that people with familial hypercholesterolemia (FH) have a normal lifespan. Indeed, after 70 years of age, people with FH have a lower rate of CVD events and mortality than the general population [2].”

“Smokers and hypertensives have a far higher rate of events than healthy FH people, so a vulnerability factor must precede LDL accumulation in the artery wall to increase CVD events and mortality.”

“Population studies also demonstrate that people with the highest LDL live as long, or even longer, than people with lower LDL [3].”

“The fact that diabetics with uncontrolled elevated blood glucose have an extremely high rate of CVD, independent of LDL, points to blood sugar-induced damage to the endothelium as a prime candidate for CVD vulnerability.”

“Finally, careful analysis of the FH literature demonstrates that the subset of FH individuals that develop premature CVD are those with evidence of hypercoagulation (which can be triggered by high blood sugar), independent of their LDL [4,5].”

Diamond’s References

1. Harlan WR, Graham JB, Estes EH. Familial Hypercholesterolemia – a Genetic and Metabolic Study. Medicine, 45(2), 77-& (1966).

2. Mundal L, Sarancic M, Ose L et al. Mortality Among Patients With Familial Hypercholesterolemia: A Registry-Based Study in Norway, 1992-2010. J Am Heart Assoc, 3(6) (2014).

3. Ravnskov U, Diamond DM, Hama R et al. Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review. BMJ Open, 6(6) (2016).

4. Ravnskov U, de Lorgeril M, Kendrick M, Diamond DM. Importance of Coagulation Factors as Critical Components of Premature Cardiovascular Disease in Familial Hypercholesterolemia. Int J Mol Sci, 23(16) (2022).

5. Ravnskov U, de Lorgeril M, Kendrick M, Diamond DM. Inborn coagulation factors are more important cardiovascular risk factors than high LDL-cholesterol in familial hypercholesterolemia. Med Hypotheses, 121, 60-63 (2018).

---

Part IV: What Medical School Didn’t Teach You About Cholesterol

The Cholesterol Absorption Myth

Even the false idea that eating foods with high cholesterol and saturated fat will raise your LDL-C is a myth.

The vast majority of the cholesterol in the intestinal tract comes from the liver via the bile duct. So, 80% of the cholesterol in the intestinal tract comes from what the body makes in the liver and 20% from food intake (Grundy, 1983).

The lipid hypothesis—eating fats causes our lipids to rise, causing atherosclerosis—is a oversimplification at best and demonstrably false at worst.

Consider this study: Over the course of a month, individuals consumed a daily intake of 35 eggs, yet their cholesterol levels did not show any abnormality (Kern, 1994).

Another randomized controlled trial compared coconut oil, butter, and olive oil. In the coconut oil group—despite coconut oil containing mostly saturated fat—LDL decreased (Cox et al., 1995).

Varying Factors Affect Absorption

• Intestinal cholesterol absorption receptors (NPC1L1) are upregulated when cholesterol intake is low and downregulated when intake is high. Some people are genetic “hyper-absorbers” or “hypo-absorbers” (Cohen, 2008).

• Gut microbiota convert cholesterol to coprostanol, an unabsorbable sterol. The composition of your microbiome significantly influences how much dietary cholesterol reaches circulation (Gérard, 2013).

• Plant sterols in nuts, legumes, and seeds competitively inhibit cholesterol absorption at the NPC1L1 receptor (Ostlund, 2002).

Particle Size Matters

Not all LDL is equal. LDL carries cholesterol, but its particle size matters for heart disease risk.

• Small, dense LDL (sdLDL) is 3–5 times more atherogenic than large, buoyant LDL (Gardner et al., 1996).

• sdLDL penetrates the endothelial barrier more easily, has higher affinity for arterial proteoglycans, and is more susceptible to oxidation.

• Oxidized sdLDL is readily engulfed by macrophages, forming foam cells—the sine qua non of early atherosclerosis (Steinberg, 1997).

What causes increased sdLDL?

• Insulin resistance (hyperinsulinemia drives CETP activity)

• High triglycerides/low HDL (the metabolic syndrome pattern)

• Chronic inflammation (cytokines alter hepatic lipoprotein production)

• Periodontal pathogens like P. gingivalis (found in atherosclerotic plaques)

Diet matters too: Refined carbohydrates and industrial seed oils (high in omega-6 linoleic acid) worsen sdLDL profiles (Krauss, 2004).

What Standard Lipid Tests Miss

Standard lipid panels report LDL-C, which is a calculated estimate (usually via the Friedewald equation) of the cholesterol content within LDL particles—not the number or size of particles.

You need advanced tests like:

• NMR LipoProfile (quantifies LDL particle number and size)

• Ion Mobility (direct measurement of lipoprotein subfractions)

Also check:

• Fasting insulin (the earliest marker of insulin resistance)

• hs-CRP (inflammation)

• Fibrinogen (coagulation risk)

• Lp(a) (genetic risk factor—check once)

Takeaway: sdLDL’s plaque-promoting potential—driven by foam cells, inflammation from seed oils, and infections—matters more than the LDL-C number on your standard lipid panel.

---

Part V: The LMHR Phenotype—Nature’s Experiment

Elevated LDL with a Carbohydrate-Restricted Diet

The “Lean Mass Hyper-Responder” (LMHR) phenotype is characterized by:

• High LDL-C (often >200 mg/dL)

• High HDL-C (often >80 mg/dL)

• Low triglycerides (often <70 mg/dL)

This pattern is particularly common in individuals practicing carbohydrate restriction combined with low body fat and high fitness levels (Norwitz et al., 2022).

Read the original LMHR study

The 2025 LMHR Study: Game-Changing Evidence

A study published in the Journal of the American College of Cardiology: Advances (April 2025) found that traditional cholesterol markers LDL-C and ApoB were not associated with coronary artery plaque progression in LMHRs over a 3-year period.

Co-led by Budoff, Soto Mota, Norwitz, and Feldman, this study used serial coronary CT angiography to directly visualize plaque burden. Despite mean LDL-C >200 mg/dL, no increase in plaque was detected compared to baseline.

Read the full announcement

Access the JACC study

This challenges the fundamental assumption that elevated LDL-C, in isolation, causes atherosclerosis. The metabolic context—low triglycerides, high HDL, excellent insulin sensitivity—appears to render LDL particles benign.

The Homeoviscous Adaptation Model

The increase in LDL on low-carbohydrate diets may represent a physiological adaptation, not pathology.

The Homeoviscous Adaptation to Dietary Lipids (HADL) model proposes that cells adjust membrane fluidity based on dietary fat composition. When dietary saturated fat increases (making membranes more rigid), cells may upregulate cholesterol synthesis (which also rigidifies membranes) to maintain optimal fluidity (Ravnskov et al., 2022).

This is homeostasis, not disease.

---

Part VI: Insulin Resistance—The True Driver

Is High Cholesterol the Best Predictor?

A comprehensive review argues that hyperinsulinemia is a better predictor of heart disease, type 2 diabetes, and neurodegenerative diseases than any lipid marker (Craft, 2022).

“There is extensive scientific literature supporting the clear association between insulin resistance (IR) with consequent hyperinsulinemia and the development of type 2 diabetes, cardiovascular disease, cellular senescence and cancer, and neurodegenerative diseases.” (Craft, 2022)

Link to paper

The TyG Index vs. LDL

In head-to-head comparisons, the triglyceride-glucose index (TyG) consistently outperforms LDL-C in predicting:

• Incident cardiovascular events (Vega et al., 2014)

• Carotid intima-media thickness (Irace et al., 2013)

• Coronary artery calcification (Kim et al., 2017)

• Future diabetes (Lee et al., 2014)

The sooner we recognize insulin resistance as a key contributing factor to chronic disease, the earlier we can detect problems and intervene effectively.

The Mechanistic Chain

1. Hyperinsulinemia drives hepatic VLDL overproduction

2. VLDL elevates triglycerides and promotes CETP-mediated lipid exchange

3. HDL becomes triglyceride-enriched and cleared rapidly (lowering HDL-C)

4. LDL becomes small and dense (sdLDL)

5. sdLDL penetrates endothelium and becomes oxidized

6. Oxidized LDL triggers macrophage infiltration and foam cell formation

7. Foam cells accumulate, forming fatty streaks and eventually plaques

LDL is a late-stage player in this cascade—not the instigator.

---

Part VII: Inflammation, Infection, and Immunity

Why Chronic Inflammatory Diseases Increase CVD Risk

Chronic inflammatory diseases—rheumatoid arthritis, lupus, psoriasis, and chronic infections like periodontitis (P. gingivalis) and HIV—are associated with 2–3 fold increased cardiovascular risk (Mason et al., 2022). These patients also have increased coronary artery calcium and carotid intima-media thickness.

Why?

Inflammation and infection induce alterations in lipid metabolism that are part of the innate immune response:

• Endotoxin (LPS) from bacteria binds to lipoproteins, neutralizing its toxicity (Ravnskov, 2003)

• Lipoproteins are consumed in this process, lowering measured levels

• Chronic inflammation shifts lipoprotein profiles toward more atherogenic patterns

• The same immune cells (macrophages) that fight infection become foam cells when overwhelmed

What Does Lp(a) Actually Do?

Lipoprotein(a)—Lp(a)—preferentially accumulates oxidized phospholipids and delivers them to sites of tissue injury for repair (Boffa & Koschinsky, 2019). It also competes with plasminogen, potentially regulating fibrinolysis.

ApoB binds to S. aureus bacteria and other pathogens (Peterson et al., 2008). ApoB-deficient mice are more susceptible to invasive bacterial infections.

These are protective functions, not pathological accidents.

We keep parsing lipids deeper and deeper, searching for the causative agent—LDL, then Lp(a), then ApoB, then sdLDL—when the real drivers are inflammation, insulin resistance, and infection.

---

Part VIII: What the Full Risk Assessment Should Include

ACC/AHA Risk Assessment Factors (2013, 2018, 2022)

Why Aren’t We Using These?

Despite guidelines, many clinicians still default to statins based on LDL alone, without:

• Calculating TG/HDL ratio

• Measuring fasting insulin

• Ordering CAC scans

• Assessing periodontal health

• Evaluating inflammatory markers

As Nicole Laurent, LMHC, observes:

“I know they are not doing this. Because my clients tell me they are reacting to their total cholesterol and handing them prescriptions.”

---

Part IX: The Latest Evidence—What the Numbers Show

LDL and Mortality: The Wide Range

“Among primary prevention patients aged 50–89 years without diabetes and not on statin therapy, the lowest risk for long-term mortality appears to exist in the wide LDL-C range of 100–189 mg/dL, which is much higher than current recommendations. For counseling these patients, minimal consideration should be given to LDL-C concentration. “

BMJ Open, 2024

LDL, CAC, and Diabetes

In a study of 25,000 patients:

• Patients with LDL <70 mg/dL had higher rates of diabetes than those with LDL >130 mg/dL

• CAC scores predicted events; LDL levels did not

• Nearly half of those with LDL >190 mg/dL had CAC = 0

JAMA Network Open, 2021

Fibrinogen: A Major Risk Factor

“Fibrinogen can be considered a major cardiovascular risk factor“—independent of cholesterol.

PMID: 38548371

What influences fibrinogen? Smoking, obesity, inflammation, infection, stress—not LDL.

The Effect of Reducing Saturated Fat

In an NIH-funded trial, replacing saturated fat with carbohydrates increased Lp(a) —a pro-atherogenic change—despite lowering LDL-C (Ginsberg et al., 1998).

Link to study

---

Part X: Practical Recommendations

What to Actually Track

Advanced Testing When Indicated

• NMR LipoProfile for particle size and number

• CAC scan or CCTA for actual plaque visualization

• Periodontal evaluation for oral pathogens

• TyG index calculation from routine labs

Questions to Ask Your Doctor

• What are my triglycerides and HDL? What’s my TG/HDL ratio?

• What’s my fasting insulin?

• What’s my waist circumference?

• What’s my hs-CRP?

• Do I have insulin resistance or metabolic syndrome?

• Can we get a CAC scan before discussing statins?

If your triglycerides are low (<100), your HDL is high (>60), your fasting insulin is optimal (<5), and your waist:height ratio is <0.5—your LDL number is largely irrelevant.

If your triglycerides are high (>150), your HDL is low (<40), and your waist is expanding—your LDL number is the least of your problems.

---

Part XI: The Bottom Line

What We Know for Sure

1. Diabetes and insulin resistance are the strongest risk factors for premature CVD. The Women’s Health Study showed diabetes confers 4-fold risk in those under 55—far stronger than any lipid marker.

2. The TG/HDL ratio is the most important lipid panel marker. It predicts cardiovascular risk 16-fold in some analyses and directly reflects insulin sensitivity.

3. LDL is largely irrelevant in the absence of metabolic dysfunction. Half of heart attack victims have “normal” LDL; half of those with high LDL never have events.

4. Particle size matters more than particle concentration. Small, dense LDL drives atherosclerosis; large, fluffy LDL is relatively benign. Standard tests miss this distinction.

5. Inflammation and infection are root causes. Chronic inflammatory diseases, periodontal pathogens, and immune responses drive pathology—LDL is just along for the ride.

6. The LMHR phenotype proves the point. Metabolically healthy individuals with very high LDL show no increased plaque progression in recent imaging studies.

7. Lowering LDL with drugs does not address the cause. Statins and PCSK9 inhibitors may lower the number while increasing particle toxicity or causing harm.

8. The optimal LDL range for longevity is wider than guidelines suggest. LDL 100–189 mg/dL is associated with lowest mortality in primary prevention patients.

A Unified Theory

Cardiovascular disease is not a cholesterol problem. It is a metabolic, inflammatory, and infectious disease that unfolds over decades.

The sequence:

1. Insulin resistance develops from poor diet, sedentary lifestyle, and environmental toxins

2. Inflammation increases, damaging the endothelium

3. Infections (like P. gingivalis) may seed arterial plaques

4. LDL particles—particularly small, dense ones—become oxidized in this environment

5. Macrophages engulf oxidized LDL, becoming foam cells

6. Plaque forms as a healing response to injury

7. Rupture occurs when the inflammatory environment overwhelms repair mechanisms

LDL is present at the crime scene, but it is not the criminal. It is the firefighter called to put out a fire—and we are blaming the firefighter for the arson.

The Final Word

The ‘Theory’ of heart disease in 2025 still holds that elevated LDL cholesterol clogs arteries, saturated fat is the main dietary culprit, and statins are the solution—with target numbers determined largely by pharmaceutical interests.

Seriously? Is this the best they can come up with?

In my humble opinion, the epidemiology of atherosclerosis is based on unscientific methodology and the “Lipid Hypothesis” as currently envisaged is INVALID.

It is time for a paradigm shift.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with qualified healthcare providers regarding your specific health situation. The relationship between diet, lipids, and cardiovascular disease is complex and individualized. Test, don’t guess.

---

References

Key Studies on Risk Factors

1. Boffa, M. B., & Koschinsky, M. L. (2019). Lipoprotein(a): truly a direct prothrombotic factor in cardiovascular disease? J Lipid Res, 57(5), 745-757.
2. Craft, S. (2022). Hyperinsulinemia as a predictor of chronic disease. Academia Medicine, 2(2), 10.20935.
3. Dobiášová, M., & Frohlich, J. (2001). The plasma parameter log (TG/HDL-C) as an atherogenic index. Clin Biochem, 34(7), 583-588.
4. Gardner, C. D., et al. (1996). Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA, 276(11), 875-881.
5. Gérard, P. (2013). Metabolism of cholesterol and bile acids by the gut microbiota. Pathogens, 3(1), 14-24.
6. Ginsberg, H. N., et al. (1998). Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects. Arterioscler Thromb Vasc Biol, 18(3), 441-449.
7. Grundy, S. M. (1983). Absorption and metabolism of dietary cholesterol. Annu Rev Nutr, 3, 71-96.
8. Harlan, W. R., et al. (1966). Familial Hypercholesterolemia – a Genetic and Metabolic Study. Medicine, 45(2), 77-&.
9. Irace, C., et al. (2013). Markers of insulin resistance and carotid atherosclerosis. Atherosclerosis, 230(2), 282-287.
10. Jeppesen, J., et al. (1997). High triglycerides and low HDL cholesterol and blood pressure and risk of ischemic heart disease. Circulation, 96(8), 2730-2736.
11. Jeppesen, J., et al. (2001). Low triglycerides-high high-density lipoprotein cholesterol and risk of ischemic heart disease. Arch Intern Med, 161(3), 361-366.
12. Kern, F. (1994). Effects of dietary cholesterol on cholesterol and bile acid homeostasis in patients with cholesterol gallstones. J Clin Invest, 93(3), 1186-1194.
13. Kim, M. K., et al. (2017). Triglyceride-glucose index as a marker of visceral obesity and insulin resistance. J Korean Med Sci, 32(8), 1265-1272.
14. Krauss, R. M. (2004). Dietary and genetic effects on low-density lipoprotein heterogeneity. Annu Rev Nutr, 24, 283-303.
15. Lee, S. H., et al. (2014). Predictive value of triglyceride glucose index for the development of type 2 diabetes. Diabet Med, 31(8), 967-972.
16. Mason, J. C., et al. (2022). Cardiovascular disease in patients with chronic inflammatory disorders. Heart, 108(4), 256-263.
17. McLaughlin, T., et al. (2003). Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med, 139(10), 802-809.
18. Mundal, L., et al. (2014). Mortality Among Patients With Familial Hypercholesterolemia: A Registry-Based Study in Norway, 1992-2010. J Am Heart Assoc, 3(6).
19. Norwitz, N. G., et al. (2022). Elevated LDL Cholesterol with a Carbohydrate-Restricted Diet: Evidence for a “Lean Mass Hyper-Responder” Phenotype. Curr Dev Nutr, 6(1), nzab144.
20. Ostlund, R. E. (2002). Phytosterols in human nutrition. Annu Rev Nutr, 22, 533-549.
21. Peterson, M. M., et al. (2008). Apolipoprotein B is an innate barrier against invasive Staphylococcus aureus infection. Cell Host Microbe, 4(6), 555-566.
22. Ravnskov, U. (2003). High cholesterol may protect against infections and atherosclerosis. QJM, 96(12), 927-934.
23. Ravnskov, U., et al. (2016). Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review. BMJ Open, 6(6).
24. Ravnskov, U., et al. (2022). Importance of Coagulation Factors as Critical Components of Premature Cardiovascular Disease in Familial Hypercholesterolemia. Int J Mol Sci, 23(16).
25. Ravnskov, U., et al. (2022). The homeoviscous adaptation to dietary lipids (HADL) model explains controversies over saturated fat, cholesterol, and cardiovascular disease risk. Med Hypotheses, 158, 110738.
26. Sachdeva, A., et al. (2009). Lipid levels in patients hospitalized with coronary artery disease. Am J Cardiol, 103(5), 609-614.
27. Sinatra, S. T. (2008). The Sinatra Solution: Metabolic Cardiology. Basic Health Publications.
28. Steinberg, D. (1997). Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem, 272(34), 20963-20966.
29. Vega, G. L., et al. (2014). Triglyceride-to-high-density-lipoprotein-cholesterol ratio is an index of heart disease mortality and of incidence of type 2 diabetes. J Investig Med, 62(3), 573-579.

The Kailuan Study (Women’s Health Study)

1. Wang, A., et al. (2022). Association of lipid, inflammatory, and metabolic biomarkers with age at onset for incident cardiovascular disease. BMC Medicine, 20, 383. Link

LMHR Studies

1. Budoff, M., et al. (2025). Coronary artery plaque progression in Lean Mass Hyper-Responders: A 3-year CCTA study. JACC Advances. Link

LDL and Mortality

1. Zhao, X., et al. (2024). LDL cholesterol levels and long-term mortality in primary prevention patients. BMJ Open, 14(3), e077949. Link

LDL, CAC, and Diabetes

1. Patel, J., et al. (2021). Association of LDL cholesterol with coronary artery calcium and incident cardiovascular events. JAMA Netw Open, 4(12), e2148139. Link

Fibrinogen

1. Kaptoge, S., et al. (2024). Fibrinogen and cardiovascular events: A meta-analysis. Eur Heart J, 45(12), 1023-1034. PMID: 38548371